HN2010002558A - DERIVADOS DE UREA MACROCICLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa - Google Patents

DERIVADOS DE UREA MACROCICLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa

Info

Publication number
HN2010002558A
HN2010002558A HN2010002558A HN2010002558A HN2010002558A HN 2010002558 A HN2010002558 A HN 2010002558A HN 2010002558 A HN2010002558 A HN 2010002558A HN 2010002558 A HN2010002558 A HN 2010002558A HN 2010002558 A HN2010002558 A HN 2010002558A
Authority
HN
Honduras
Prior art keywords
inhibitors
sulfamida
macrociclicos
tafia
urea
Prior art date
Application number
HN2010002558A
Other languages
English (en)
Inventor
Kallus Christopher
Broenstrup Markk
Evers Andreas
Globisch Anja
Schreuder Herman
Wagner Michael
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HN2010002558A publication Critical patent/HN2010002558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I) QUE SON INHIBIDORES DE LA FIBRINOLISIS ACTIVABLE POR TROMBINA ACTIVADA. LOS COMPUESTOS DE LA FORMULA I SON ADECUADOS PARA LA FABRICACION DE MEDICAMENTOS PARA LA PROFILAXIS, PREVENCION SECUNDARIA Y TERAPIA DE UNO O MAS TRASTORNOS ASOCIADOS CON TROMBOSIS, HIPERCOAGULABILIDAD O CAMBIOS FIBROTICOS.
HN2010002558A 2008-06-06 2010-12-03 DERIVADOS DE UREA MACROCICLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa HN2010002558A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06

Publications (1)

Publication Number Publication Date
HN2010002558A true HN2010002558A (es) 2012-08-28

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010002558A HN2010002558A (es) 2008-06-06 2010-12-03 DERIVADOS DE UREA MACROCICLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa

Country Status (35)

Country Link
US (5) US8580777B2 (es)
EP (1) EP2300462B1 (es)
JP (1) JP5531011B2 (es)
KR (1) KR101673886B1 (es)
CN (1) CN102056922B (es)
AR (1) AR072007A1 (es)
AU (1) AU2009254257B2 (es)
BR (1) BRPI0913349A2 (es)
CA (1) CA2726554C (es)
CL (1) CL2009001358A1 (es)
CO (1) CO6321271A2 (es)
CR (1) CR11807A (es)
CY (1) CY1115604T1 (es)
DK (1) DK2300462T3 (es)
DO (1) DOP2010000363A (es)
EC (1) ECSP10010655A (es)
ES (1) ES2494390T3 (es)
HK (1) HK1152936A1 (es)
HN (1) HN2010002558A (es)
HR (1) HRP20140787T1 (es)
IL (1) IL209772A (es)
MA (1) MA32322B1 (es)
MX (1) MX2010012793A (es)
NI (1) NI201000203A (es)
NZ (1) NZ589671A (es)
PL (1) PL2300462T3 (es)
PT (1) PT2300462E (es)
RU (1) RU2502736C2 (es)
SI (1) SI2300462T1 (es)
SV (1) SV2010003747A (es)
TW (1) TWI455928B (es)
UA (1) UA104002C2 (es)
UY (1) UY31868A (es)
WO (1) WO2009146802A1 (es)
ZA (1) ZA201007719B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5531011B2 (ja) 2008-06-06 2014-06-25 サノフイ ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体
BRPI0914323A2 (pt) 2008-06-23 2017-03-28 Astrazeneca Ab composto, formulação farmacêutica, uso de um composto, e, métodos de tratamento de uma condição e de tratamento e prevenção de distúrbios
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
EP2822953B9 (en) * 2012-03-06 2017-06-21 Pfizer Inc Macrocyclic derivatives for the treatment of proliferative diseases
AU2014280329A1 (en) * 2013-06-10 2016-01-07 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
EP1130022B1 (en) * 2000-02-29 2009-07-22 Universita Degli Studi di Firenze 3-Aza-6,8-dioxabicyclo[3.2.1]octanes and analogues and combinatorial libraries containing them
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
JP5531011B2 (ja) 2008-06-06 2014-06-25 サノフイ ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体

Also Published As

Publication number Publication date
PL2300462T3 (pl) 2014-10-31
DOP2010000363A (es) 2010-12-15
CO6321271A2 (es) 2011-09-20
IL209772A (en) 2016-04-21
IL209772A0 (en) 2011-02-28
ZA201007719B (en) 2011-07-27
US9309207B2 (en) 2016-04-12
AR072007A1 (es) 2010-07-28
PT2300462E (pt) 2014-08-05
CA2726554C (en) 2015-02-24
TW201008917A (en) 2010-03-01
HRP20140787T1 (hr) 2014-11-21
CN102056922A (zh) 2011-05-11
KR101673886B1 (ko) 2016-11-08
NI201000203A (es) 2011-09-29
UA104002C2 (ru) 2013-12-25
US20160251324A1 (en) 2016-09-01
NZ589671A (en) 2012-03-30
JP2011521981A (ja) 2011-07-28
HK1152936A1 (en) 2012-03-16
UY31868A (es) 2010-01-05
US20160024033A1 (en) 2016-01-28
US9688645B2 (en) 2017-06-27
BRPI0913349A2 (pt) 2015-11-24
US9126955B2 (en) 2015-09-08
KR20110020795A (ko) 2011-03-03
JP5531011B2 (ja) 2014-06-25
RU2010154089A (ru) 2012-07-20
US8722655B2 (en) 2014-05-13
CA2726554A1 (en) 2009-12-10
CY1115604T1 (el) 2017-01-04
WO2009146802A1 (de) 2009-12-10
EP2300462A1 (de) 2011-03-30
CR11807A (es) 2011-02-16
US20140206760A1 (en) 2014-07-24
DK2300462T3 (da) 2014-08-18
MX2010012793A (es) 2010-12-14
MA32322B1 (fr) 2011-05-02
US20110178130A1 (en) 2011-07-21
TWI455928B (zh) 2014-10-11
SI2300462T1 (sl) 2014-09-30
ECSP10010655A (es) 2011-01-31
SV2010003747A (es) 2011-03-15
RU2502736C2 (ru) 2013-12-27
US8580777B2 (en) 2013-11-12
CL2009001358A1 (es) 2009-11-27
US20140039011A1 (en) 2014-02-06
EP2300462B1 (de) 2014-05-21
ES2494390T3 (es) 2014-09-15
AU2009254257B2 (en) 2013-11-21
CN102056922B (zh) 2013-11-20
AU2009254257A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
HN2010002558A (es) DERIVADOS DE UREA MACROCICLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
BR112018010118A2 (pt) inibidores de cxcr2
CR20110103A (es) Heteroarilos sustituidos
UY28868A1 (es) Ácidos heterociclilacéticos como inhibidores de tafla.
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
ECSP13012612A (es) Derivados de quinazolin-4-(3h)-ona utilizados como inhibidores de p13 cinasa
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR11309A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonista de la histamnia-3
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
UY34767A (es) Inhibidores cíclicos del enlace éter de dgat1
CO6300955A2 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3
GT201400090A (es) 2-tiopirimidinonas
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
UY32385A (es) Amidas de pirazinona sustituida
PE20151003A1 (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico
CU20110020A7 (es) Compuestos de fenantrenona, composiciones y métodos
UY30760A1 (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia
CU20100047A7 (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
CU20100045A7 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
AR085953A1 (es) Polimeros de bencilo metarreticulados